Louise Tofts
NSW, Australia · RMSANZ Member (Ordinary Membership) · FAFRM
Institution(s): AU
MM 1 - Metropolitan(Postcode: 2109)
Click a bar to filter publications by year
Consensus Guidelines for the Use of Vosoritide in Children with Achondroplasia in Australia
BioMarin Pharmaceutical · 2024
Breadth and visibility of children’s lower limb chronic musculoskeletal pain: a scoping review
Medical Research Future Fund · 2024(MRF2015863)
Variability of joint hypermobility in children: a meta-analytic approach to set cut-off scores
Monash University · 2024
Pediatric joint hypermobility: a diagnostic framework and narrative review
Ehlers-Danlos Society · 2023
Vosoritide therapy in children with achondroplasia aged 3−59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial
BioMarin Pharmaceutical · 2023
Australian guidelines for the management of children with achondroplasia
Macquarie University · 2023
AB1783-HPR VALIDATION OF AN ELECTRONIC VISUAL ANALOG SCALE APP FOR PAIN EVALUATION IN CHILDREN AND ADOLESCENTS WITH SYMPTOMATIC HYPERMOBILITY: CROSS-SECTIONAL STUDY
Eli Lilly and Company · 2023
AB1783-HPR VALIDATION OF AN ELECTRONIC VISUAL ANALOG SCALE APP FOR PAIN EVALUATION IN CHILDREN AND ADOLESCENTS WITH SYMPTOMATIC HYPERMOBILITY: CROSS-SECTIONAL STUDY
Pfizer · 2023
AB1783-HPR VALIDATION OF AN ELECTRONIC VISUAL ANALOG SCALE APP FOR PAIN EVALUATION IN CHILDREN AND ADOLESCENTS WITH SYMPTOMATIC HYPERMOBILITY: CROSS-SECTIONAL STUDY
Gilead Sciences · 2023
Lifetime impact of achondroplasia: Current evidence and perspectives on the natural history
Osteogenesis Imperfecta Foundation · 2021
A50738324180000-0002-3961-0493